Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial - Meng, Xiangrui; Yang, Xiuli; Hong, Yonggui; Wang, Wenkang; Zhang, Zhiye; Xia, Jin; Chen, Yunfang; Zhou, Yue; Lu, Taiying; Song, Min; Shan, Zhengzheng; Wu, Tao; et al. (Molecular cancer, 2025)
Keywords: Adult; Aged; Anlotinib; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Benmelstobart; Biomarkers, Tumor; Cancer; Chemotherapy; Clinical trials; Esophageal cancer; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - mortality; Esophageal Neoplasms - pathology; Esophageal squamous cell carcinoma; Esophageal Squamous Cell Carcinoma - drug therapy; Esophageal Squamous Cell Carcinoma - genetics; Esophageal Squamous Cell Carcinoma - mortality; Esophageal Squamous Cell Carcinoma - pathology; Female; Humans; Indoles - administration & dosage; Ipilimumab; Male; Middle Aged; Mutation; Neoplasm Staging; Next-generation sequencing; PD-L1; Quinolines - administration & dosage; Squamous cell carcinoma; TP53+/FAT1+/NOTCH3; Treatment Outcome; China; PD-L1; TP53+/FAT1+/NOTCH3; Benmelstobart; Esophageal squamous cell carcinoma; Anlotinib; Next-generation sequencing